A Phase 4 interventional study of dronedarone 400 mg Oral Tablet and Placebo in Atrial Fibrillation and Atrial Fibrillation Recurrent, sponsored by Tulane University School of Medicine. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.
Sponsored by Tulane University School of Medicine · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.
Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 26th largest by enrollment, is one of 2 that started in 2021, is one of 11 in phase 4, and was the 21st registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:
Shanghai East Hospital · Sites in China
Ages 18–80
Inha University Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8 · Phase 4 11
First in 2001; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 164 across the 26 interventional studies. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 26 have an industry lead sponsor. The 10 most frequent:
Tulane University School of Medicine is the lead sponsor of 20 studies on the registry; 1 is open to participants now.
Tulane University School of Medicine has 3 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing dronedarone in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients who have undergone cardiac ablation will be randomized and blinded to one of two groups; one group will receive dronedarone while the other group will receive a placebo. The incidence of atrial fibrillation recurrence, as well as atrial fibrosis progression, will be analyzed between the two trial groups.
The purpose of this trial is to determine whether dronedarone is effective in slowing the progression of fibrosis and decreasing atrial fibrillation recurrence in patients who have undergone ablation therapy.
Patients with atrial fibrillation (AF) undergoing ablation will be stratified by age and gender (>65 years and \<65 years, male and female) as well as by type of atrial fibrillation (paroxysmal, persistent, etc.) and then randomized to one of two trial groups. They will either receive dronedarone 400 mg BID (twice daily) (treatment group) or placebo (control group). The control group will be started on placebo, and treating physicians will be advised to limit the initiation of anti-arrhythmic drugs (standard of care, SOC) to necessary cases only, avoiding amiodarone and dronedarone.
Each patient will receive a pre-ablation Cardiac Magnetic Resonance imaging (CMR) (SOC) scan, followed by scans at 3 and 12-month post-ablation. Quality of Life (QoL) changes will be evaluated from baseline and at 3 months and 12-months via the Atrial Fibrillation Effect on Quality-Of-Life (AFEQT) online questionnaire form. AF burden (frequency, duration and severity of an AF episode) if present, will be evaluated from baseline and at 3 months and 12-months via the Atrial Fibrillation Severity Scale (AFSS) online questionnaire form.
Patients will be followed post-ablation for AF recurrence and burden assessment with a continuous 30-day ECG wearable patch starting at discharge (SOC), then at 3,6,9 and 12 months post-ablation
Phone call visits will occur at 6 and 9 months to monitor for medication compliance as well as to assess that devices are working accordingly. Evaluation of adverse events (AE's) as well as whether a patient has reached any trial endpoints will be analyzed at this time.
Physicians will be advised to avoid adjustments in drug therapy unless necessary (severely symptomatic patients, patients with heart failure). Severely symptomatic patients will be defined as, patients with non-tolerated palpitations or chest pain, dizziness, syncope, dyspnea, or suddenly reduced ability to exercise.
Any initiation or change of an anti-arrhythmic treatment in the treatment or control group will be considered as a secondary endpoint. Patients will continue to be monitored for fibrosis progression and AF burden via CMR scans and ECG wearable devices until the end of the follow-up period. In the case of AF recurrence after ablation, anti-arrhythmic drugs (AAD) initiation or change will be left to the discretion of the treating physician.
Inclusion Criteria: Patients must meet the following criteria to be enrolled in the trial.
Exclusion Criteria: Patients will be excluded from enrollment if any of the following criteria are present.
Pre-menopausal (last menstruation \<1 year prior to screening) who:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dronedarone 400 mg orally, twice per day (BID)
Drug: dronedarone 400 mg Oral Tablet
Placebo tablet orally, twice per day (BID)
Drug: Placebo
Dronedarone is an anti-arrhythmic drug with properties belonging to Vaughan-Williams class I-IV. Participants will receive dronedarone 400 mg tablet, to be taken orally and twice daily for 52 weeks.
Also known as: Multaq®
Participants will receive a placebo tablet matching the physical appearance of dronedarone, to be taken orally and twice daily for 52 weeks.
Post-ablation Atrial Fibrillation Recurrence
Investigators monitored subjects upon discharge, 24-48 hours after AF ablation. This was recorded by either the occurrence of a single positive atrial arrhythmias (AA) ECG reading on a 12-lead ECG, Holter monitor, obtained on the daily event strips from the Preventice monitoring device, or 30-day monitoring patch.
Time frame: Up to 56 weeks. From date of ablation until the date of first documented Atrial Fibrillation recurrence, whichever came first, assessed up to 56 weeks.
Post-ablation Atrial Fibrillation Recurrence Documented by an AAD Initiation
New anti-arrhythmic drug (AAD) initiation for AF recurrence after AF ablation, including initiation of the treatment during the blanking period, or with no available positive ECG reading.
Time frame: Up to 56 weeks. From date of ablation until the date of first documented Atrial Fibrillation recurrence, whichever came first, assessed up to 56 weeks.
Atrial Fibrillation Episodes
Atrial arrhythmia (AA) episodes associated with palpitations, chest pain, dyspnea, dizziness, syncope, or unusual fatigue and weakness were assessed using the Atrial Fibrillation Severity Scale (AFSS) questionnaire. The AFSS is a validated questionnaire designed to measure the burden of atrial arrhythmias, including atrial fibrillation and other irregular heart rhythms. The AA symptom burden score is derived from the AFSS summary score, which averages the frequency, duration, and patient-perceived severity of AA episodes. The AFSS symptom burden score ranges from 3 to 30, with higher scores indicating greater AA burden. Subscale scores (frequency, duration, and severity) are each rated on a scale of 1 to 10 and are averaged to calculate the total burden score. Patients completed the AFSS at baseline, 3 months, and 12 months. Reported data in the results table reflect the mean score at the 12-month time point.
Time frame: At baseline, at month 3, at month 12
Repeat Cardiac Ablation
Whether patients in either treatment arm require a repeat cardiac ablation.
Time frame: 1 year
Cardioversion
Whether patients in either treatment arm require cardioversion.
Time frame: 1 year
Atrial Fibrillation Burden
The percentage of time a patient is in atrial fibrillation during the monitoring period, 24-48 hours and, at 3 months and 12 months post-ablation. Burden will be recorded as a time-weighted average (%) based on data from wearable devices.
Time frame: 1 year
Quality of Life (Online Questionnaire Form)
Quality of life (QoL) was assessed through the Atrial Fibrillation Severity Scale (AFSS), a validated instrument that evaluates the impact of AF across multiple domains, including symptom burden, health care utilization, and overall well-being. The Global Well-being domain of the AFSS is assessed using a single-item question (A4), which measures overall quality of life on a scale from 1 to 10, where higher scores indicate better quality of life. Patients completed the questionnaire at baseline, 3 months, and 12 months. The reported data in the results table reflect the mean score at the 12-month time point.
Time frame: At baseline, at month 3, at month 12
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Assessment of adverse events related to treatment given. Evaluated at 3, 12 months visits and during 6 \& 9 month phone call visits.
Time frame: Through trial completion, up to 56 weeks.
Hospitalization
Records of any cardiac events requiring hospitalization.
Time frame: 1 year
Mortality
Records of mortality associated with cardiovascular events.
Time frame: 1 year
Stroke/ Transient Ischemic Attacks (TIA)
Records of stroke or TIA based on cardiac emboli.
Time frame: 1 year
| Milestone | Treatment Group | Control Group |
|---|---|---|
| Started | 12 | 10 |
| Completed | 6 | 7 |
| Not completed | 6 | 3 |
Investigators monitored subjects upon discharge, 24-48 hours after AF ablation. This was recorded by either the occurrence of a single positive atrial arrhythmias (AA) ECG reading on a 12-lead ECG, Holter monitor, obtained on the daily event strips from the Preventice monitoring device, or 30-day monitoring patch.
| Participants | Treatment Group | Control Group |
|---|---|---|
| Post-ablation Atrial Fibrillation Recurrence | 2 | 1 |
New anti-arrhythmic drug (AAD) initiation for AF recurrence after AF ablation, including initiation of the treatment during the blanking period, or with no available positive ECG reading.
| Participants | Treatment Group | Control Group |
|---|---|---|
| Post-ablation Atrial Fibrillation Recurrence Documented by an AAD Initiation | 1 | 2 |
Atrial arrhythmia (AA) episodes associated with palpitations, chest pain, dyspnea, dizziness, syncope, or unusual fatigue and weakness were assessed using the Atrial Fibrillation Severity Scale (AFSS) questionnaire. The AFSS is a validated questionnaire designed to measure the burden of atrial arrhythmias, including atrial fibrillation and other irregular heart rhythms. The AA symptom burden score is derived from the AFSS summary score, which averages the frequency, duration, and patient-perceived severity of AA episodes. The AFSS symptom burden score ranges from 3 to 30, with higher scores indicating greater AA burden. Subscale scores (frequency, duration, and severity) are each rated on a scale of 1 to 10 and are averaged to calculate the total burden score. Patients completed the AFSS at baseline, 3 months, and 12 months. Reported data in the results table reflect the mean score at the 12-month time point.
| Scores on a scale | Treatment Group | Control Group |
|---|---|---|
| Atrial Fibrillation Episodes | 7.5 ± 1.73 | 7.8 ± 2.17 |
Whether patients in either treatment arm require a repeat cardiac ablation.
| Participants | Treatment Group | Control Group |
|---|---|---|
| Repeat Cardiac Ablation | 1 | 0 |
Whether patients in either treatment arm require cardioversion.
| Participants | Treatment Group | Control Group |
|---|---|---|
| Cardioversion | 2 | 1 |
The percentage of time a patient is in atrial fibrillation during the monitoring period, 24-48 hours and, at 3 months and 12 months post-ablation. Burden will be recorded as a time-weighted average (%) based on data from wearable devices.
| Percentage of time | Treatment Group | Control Group |
|---|---|---|
| Atrial Fibrillation Burden | 9 ± 4.55 | 4.5 ± 5.8 |
Quality of life (QoL) was assessed through the Atrial Fibrillation Severity Scale (AFSS), a validated instrument that evaluates the impact of AF across multiple domains, including symptom burden, health care utilization, and overall well-being. The Global Well-being domain of the AFSS is assessed using a single-item question (A4), which measures overall quality of life on a scale from 1 to 10, where higher scores indicate better quality of life. Patients completed the questionnaire at baseline, 3 months, and 12 months. The reported data in the results table reflect the mean score at the 12-month time point.
| Scores on a scale | Treatment Group | Control Group |
|---|---|---|
| Quality of Life (Online Questionnaire Form) | 8.8 ± 1.30 | 10 ± 0 |
Assessment of adverse events related to treatment given. Evaluated at 3, 12 months visits and during 6 \& 9 month phone call visits.
| Events | Treatment Group | Control Group |
|---|---|---|
| Anemia | 1 | 0 |
| Fatigue | 1 | 0 |
| Hypoxemia | 1 | 0 |
| Elevated creatinine | 1 | 0 |
| Thrombocytopenia | 1 | 0 |
| Dyspnea | 1 | 0 |
| Dyspnea on effort | 1 | 0 |
| Increased Troponin | 1 | 0 |
| Intermittent Nausea | 1 | 0 |
| Intermittent Headache | 1 | 0 |
| Upset Stomach | 1 | 0 |
| Right shoulder pain | 1 | 0 |
| Right rotator cuff tear | 1 | 0 |
| Elevated uric acid levels | 0 | 1 |
| Excessive flatulence | 0 | 1 |
| Hemorrhoids | 1 | 0 |
| Prostate hyperplasia | 1 | 0 |
| Hypertension | 0 | 1 |
| Worsening of Hyperlipidemia | 0 | 1 |
| Right lung mass | 0 | 1 |
| Increased shoulder pain | 0 | 1 |
| Leukocytosis | 0 | 1 |
| Nausea | 1 | 0 |
| Diarrhea | 1 | 0 |
| Rash on Chest | 1 | 0 |
| Spinal Stenosis | 1 | 0 |
| Urinary incontinence | 1 | 0 |
| Erectile dysfunction | 1 | 0 |
Records of any cardiac events requiring hospitalization.
| Events | Treatment Group | Control Group |
|---|---|---|
| Anemia | 1 | 0 |
| Chest Pain | 0 | 1 |
| Dizziness | 0 | 1 |
| Dyspnea | 0 | 1 |
| Hematuria | 0 | 1 |
| GERD | 0 | 1 |
| Peripheral neuropathy | 1 | 0 |
| Increased Troponin | 1 | 0 |
| Right lower extremity swelling | 0 | 1 |
| Left lower extremity swelling | 0 | 1 |
| Left upper extremity swelling | 0 | 1 |
| Acute gout flare-up | 0 | 1 |
| Cellulitis | 0 | 1 |
| Fluid Overload | 0 | 1 |
| Acute Kidney Injury | 0 | 1 |
| Acute Tubular Necrosis | 0 | 1 |
| Hyperkalemia | 0 | 1 |
| Hypotension | 0 | 1 |
Records of mortality associated with cardiovascular events.
| Participants | Treatment Group | Control Group |
|---|---|---|
| Mortality | 0 | 0 |
Records of stroke or TIA based on cardiac emboli.
| Participants | Treatment Group | Control Group |
|---|---|---|
| Stroke/ Transient Ischemic Attacks (TIA) | 0 | 0 |
Collected over 13 Months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Group | 0/12 (0%) | 2/12 (16.7%) | 2/12 (16.7%) |
| Control Group | 0/10 (0%) | 3/10 (30%) | 3/10 (30%) |
| Event | Treatment Group | Control Group |
|---|---|---|
| HospitalizationCardiac disorders | 2/12 | 3/10 |
| DizzinessEar and labyrinth disorders | 0/12 | 1/10 |
| DyspneaCardiac disorders | 0/12 | 1/10 |
| HematuriaRenal and urinary disorders | 0/12 | 1/10 |
| GERDGastrointestinal disorders | 0/12 | 1/10 |
| Chest PainCardiac disorders | 0/12 | 1/10 |
| Right lower extremity swellingVascular disorders | 0/12 | 1/10 |
| Left lower extremity swellingVascular disorders | 0/12 | 1/10 |
| Left upper extremity swellingVascular disorders | 0/12 | 1/10 |
| Acute gout flare-upMusculoskeletal and connective tissue disorders | 0/12 | 1/10 |
| Event | Treatment Group | Control Group |
|---|---|---|
| HypertensionCardiac disorders | 0/12 | 1/10 |
| Worsening of HyperlipidemiaCardiac disorders | 0/12 | 1/10 |
| LeukocytosisBlood and lymphatic system disorders | 0/12 | 1/10 |
| Right lung massRespiratory, thoracic and mediastinal disorders | 0/12 | 1/10 |
| Excessive flatulenceGastrointestinal disorders | 0/12 | 1/10 |
| Increased shoulder painMusculoskeletal and connective tissue disorders | 0/12 | 1/10 |
| Elevated uric acid levelsMusculoskeletal and connective tissue disorders | 0/12 | 1/10 |
| DyspneaCardiac disorders | 1/12 | 0/10 |
| Dyspnea on effortCardiac disorders | 1/12 | 0/10 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/12 | 0/10 |
| Age, Continuous(years) | Treatment Group | Control Group | Total |
|---|---|---|---|
| Median | 66 (55.25 to 78.25) | 64.50 (52.50 to 69.75) | 66 (53.75 to 72.50) |
| Sex: Female, Male(Participants) | Treatment Group | Control Group | Total |
|---|---|---|---|
| Female | 6 | 5 | 11 |
| Male | 6 | 5 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Group | Control Group | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 10 | 9 | 19 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Region of Enrollment(participants) | Treatment Group | Control Group | Total |
|---|---|---|---|
| United States | 12 | 10 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2021 to primary completion in Dec 2022, 19 months.
Results were first posted in Oct 2025, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dronedarone
Tulane University School of Medicine